In her role with Precede Biosciences, an early-stage liquid biopsy company, Corrie drives external research and collaborations focused on maximizing the impact of a novel technology to improve the lives of patients. She is the former Deputy Director and remains a Strategic Advisor to Count Me In, a patient-partnered genomics initiative of the Broad Institute of MIT and Harvard. A trained cancer research scientist with a Ph.D. in biochemistry, Corrie co-developed and oversaw the creation of a nation-wide clinico-genomics data platform built in lockstep with the community of cancer patients in each study. An angiosarcoma survivor, she is also a passionate patient advocate who co-founded and serves as President of Angiosarcoma Awareness, a patient-driven nonprofit that supports research and awareness efforts surrounding this rare type of cancer that affects the inner lining of blood vessels or lymph vessels.
Alliance for Rare Cancers I Jedi Rare Cancer Foundation
P.O. Box 683501, Park City, Utah 84068
The Alliance for Rare Cancers is a fiscally sponsored program of the Jedi Rare Cancer Foundation, a 501(c)(3) nonprofit organization, accepting tax-deductible donations from individuals, corporations, family-advised funds, and foundations. Federal Tax ID 86-2610819. All donations are tax deductible as allowed by law.I
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.